HOPKINTON, Mass., Feb. 6 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. , a biotechnology company focused on diagnostic and therapeutic products for central nervous system disorders, today announced the appointment of Dr. Henry Brem and Gary Frashier as new members of the Company’s Board of Directors.
“We welcome both of these highly qualified individuals to the Boston Life Sciences board,” comments Peter G. Savas, Chairman and CEO. “I believe that the right board is made up of people who: believe in the potential social and economic value of the Company’s programs; bring an inventory of complimentary skills, experiences and relationships; and work effectively together with each other, the officers and the shareholders. As a physician, neurosurgeon and director of neurosurgery for Johns Hopkins, Henry provides medical and clinical perspective to the board. His experience on advisory boards of biotech, major pharmaceutical and professional organizations will provide invaluable knowledge as we develop and execute our product strategies in nerve repair. Gary brings over 25 years of experience as a CEO and independent director of a variety of drug development and biotechnology companies. This experience and operational knowledge will be of immense benefit to our company.”
Henry Brem, M.D., has been a professor at Johns Hopkins University School of Medicine since 1984. He serves as the Director of the Department of Neurosurgery, Harvey Cushing Professor of Neurosurgery, Professor of Ophthalmology, and Oncology. He is also Director of the Hunterian Neurosurgical Research Laboratory. Dr. Brem obtained his bachelor’s degree from NYU and received his medical degree from Harvard Medical School. He trained in surgery at the Peter Bent Brigham Hospital in Boston and in neurosurgery at the Neurological Institute of New York at Columbia University. Brem has authored more than 150 articles in scientific journals. He is responsible for developing Gliadel(R) wafer, a brain cancer treatment, from concept through FDA approval. Dr. Brem holds several patents for therapeutic agents and delivery methods.
Gary Frashier, through his company Management Associates, has been a strategic consultant to emerging growth companies in the life sciences field for the last five years. From 1990 until September 1998, he served as Chief Executive Officer of OSI Pharmaceuticals, Inc., a biotechnology company, and, from January 1997 until September 2000, as its Chairman of the Board. From 1987 until 1990, he served as President and CEO of Genex Corporation, a protein engineering company, and from 1984 until 1987, as Chairman and CEO of Continental Water Systems, Inc., a manufacturer and marketer of equipment to produce high purity water used by the pharmaceutical, medical, electronics and research industries. Mr. Frashier also served as Executive Vice President of Millipore Corporation, a provider of products and services to biopharmaceutical, manufacturing, clinical, analytical and research laboratories, and President of Millipore’s Waters Associates subsidiary. Mr. Frashier serves on the Board of Directors of Tanox Inc., a Texas-based biopharmaceutical company, and Inex Pharmaceuticals Corporation, a Canadian- based biopharmaceutical company. Mr. Frashier has a B.S in Chemical Engineering from Texas Tech University and received his M.B.A. from the Massachusetts Institute of Technology.
The other current members of the Boston Life Sciences, Inc. board are William Guinness, Robert Langer, Michael Mullen, John Preston and Peter Savas.
About Boston Life Sciences, Inc.
Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinson’s Disease (PD) and Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. The company’s research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson’s disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. BLSI’s current research collaborations include Harvard Medical School and Children’s Hospital Boston.
Gliadel(R) wafer is a trademark of MGI Pharma.
Safe Harbor
The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Boston Life Sciences’ future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and Cethrin, the prospects of the Company’s CNS therapeutics program, the Company’s strategies to develop and commercialize axon regeneration technologies and the breadth of the Company’s technologies and intellectual property portfolio. Forward- looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 filed with the Securities and Exchange Commission under the section “Risk Factors,” as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.
Contact: Sharon Correia -- 508-497-2360 ext 224
Boston Life Sciences, Inc. scorreia@bostonlifesciences.com
Boston Life Sciences, Inc.
CONTACT: Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360 ext224, or scorreia@bostonlifesciences.com
Web site: http://www.bostonlifesciences.com/
